Sort By

STAT5b Polyclonal Antibody (Bethyl Laboratories)

STAT5b Polyclonal Antibody for Western Blot, IHC

STAT5B Polyclonal Antibody (Proteintech)

STAT5B Polyclonal Antibody for Western Blot

STAT5B Polyclonal Antibody (Proteintech)

STAT5B Polyclonal Antibody for Western Blot, IF, ICC, IHC (P), IP

STAT5b Polyclonal Antibody (Bethyl Laboratories)

STAT5b Polyclonal Antibody for Western Blot, IHC, IP

STAT5B Monoclonal Antibody (1D9B11) (Proteintech)

STAT5B Monoclonal Antibody for Western Blot

STAT5 alpha/beta Monoclonal Antibody (ST5-8F7) (Invitrogen™)

STAT5 alpha/beta Monoclonal Antibody for Western Blot, IF, ICC, ELISA

LanthaScreen™ STAT5 TF-1 Cell Line

LanthaScreen® GFP Cellular Assays allow for the analysis of post-translational modifications for a number of target proteins in an live-cell context. In hematopoeitic cells, the JAK2⁄STAT5 signaling pathway plays an essential role in blood cell formation in response to cytokines such as GM-CSF, IL-3, and EPO. In this pathway, binding of these cytokines to their respective cell surface receptors results in the activation of JAK2, which in turn phospho-activates STAT5 proteins at specific tyrosine residues (Tyr-694⁄699). LanthaScreenTM-STAT5 TF-1 is a human hematopoeitic cell line which constitutively expresses GFP-STAT5 fusion proteins. The JAK2⁄STAT5 signaling pathway is known to be functionally intact in this cell line, therefore the GFP-STAT5 fusion protein serves as a substrate for the inducible phosphorylation by JAK2. Using this cell line, a homogenous immuno-assay has been developed in which the phosphorylation state of GFP-STAT5 is detected in cell lysates using a LanthaScreenTM Terbium-anti-mouse and anti-phospho STAT5 [pTyr694⁄699] antibody pair, in a time-resolved FRET (TR-FRET) readout. GFP-STAT5 Lentivirus was transduced into TF-1 cells followed by selection with Blasticidine. This cell line is a clonal population isolated by flow cytometry using GFP fluorescence as sorting marker, and has been screened for the constitutive expression of GFP-STAT5 fusion protein. Using a lytic TR-FRET immuno-assay, this cell line is validated for EC50 and Z' under optimized conditions using GM-CSF as an agonist for JAK2 -mediated GFP-STAT5 phosphorylation. This assay has also been tested for assay performance under variable experimental conditions, including cell plating density, stimulation time, DMSO tolerance and lysis⁄equilibration time.

Phospho-STAT5 beta (Tyr694) Monoclonal Antibody (ST5P-4A9) (Invitrogen™)

Phospho-STAT5 beta (Tyr694) Monoclonal Antibody for Western Blot, ELISA

STAT5 beta Recombinant Polyclonal Antibody (13HCLC) (Invitrogen™)

STAT5 beta Recombinant Polyclonal Antibody for Western Blot, ChIP

LanthaScreen™ STAT5 (JAK2 V617F) U2OS Cell Line

LanthaScreen® GFP Cellular Assays allow for the analysis of post-translational modifications for a number of target proteins in an live-cell context. The JAK2⁄STAT5 signaling pathway plays an essential role in blood cell formation in response to cytokines such as GM-CSF, IL-3, and EPO. The recent discovery of an activating mutation in JAK2 (V617F) present in high percentage of myeloproliferative disease (MPD) patients suggests that this mutant JAK2 activity is a potential therapeutic target for certain forms of MPD. The assay described in this summary makes use of a cell line engineered for expression of the constitutively-active mutant kinase JAK2 V617F. By co-expressing GFP-STAT5 in this background, the phosphorylation state of STAT5 (specifically residue Tyr 694⁄699) can be modulated with JAK2 V617F inhibitors and analyzed in cell lysates using an anti-STAT5 [pTyr 694⁄699] and LanthaScreenTM terbium-anti-mouse antibody pair. GFP-STAT5 Lentivirus was transduced into U2OS cells followed by selection with Blasticidin. The selected pool was then transfected with a GST-JAK2 V617F construct using LipofectamineTM LTX, followed by selection with Geneticin. This cell line is a clonal population isolated by flow cytometry using GFP fluorescence as sorting marker, and has been screened for the constitutive expression of GFP-STAT5 and GST-JAK2 V617F. Using a lytic TR-FRET immuno-assay, this cell line is validated for IC50 and Z' under optimized conditions using JAK Inhibitor I (Pyridone 6) as a small molecule inhibitor for JAK2 V617F-mediated GFP-STAT5 phosphorylation. This assay has also been tested for assay performance under variable experimental conditions, including cell plating density, stimulation time, DMSO tolerance and lysis⁄equilibration time.

STAT5 alpha/beta Human InstantOne™ ELISA Kit (Invitrogen™)

STAT5 alpha/beta Human InstantOne™ ELISA Kit for ELISA

STAT5 beta Polyclonal Antibody (Invitrogen™)

STAT5 beta Polyclonal Antibody for Western Blot, IHC (P), IP, ELISA, GS

STAT5 beta Recombinant Rabbit Monoclonal Antibody (13H20L4) (Invitrogen™)

STAT5 beta Recombinant Monoclonal Antibody for Western Blot, IF, ICC, IHC (P), ChIP

STAT5 beta Monoclonal Antibody (ST5b-10G1) (Invitrogen™)

STAT5 beta Monoclonal Antibody for Western Blot, IF, ICC, IHC (P), IP, ChIP, ELISA, GS

Phospho-STAT5 alpha (Tyr694) Polyclonal Antibody (Invitrogen™)

Phospho-STAT5 alpha (Tyr694) Polyclonal Antibody for Western Blot, IHC, ELISA